Perioperative immunotherapy
Immune checkpoint inhibitors given before and after cancer surgery.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 154, 179, 258, 314, 348.
New guidelines and consensus this year
- 2026 Revised recommendations of the American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancerJ Thorac Cardiovasc Surg2026 Sep 25
- [Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)]Zhonghua Zhong Liu Za Zhi2026 Sep 23
- [Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)]Zhonghua Yi Xue Za Zhi2026 Sep 22
- European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026Eur J Cancer2026 Jul 26
- Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP)Eur J Cancer2026 Jun 3
All papers from the last 12 months
2,034 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Early local immune activation following intra-operative radiotherapy in human breast tissueOncoimmunology2026 Dec 31PMID 41943280
- Advances in neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma (Review)Oncol Rep2026 DecPMID 42885303Review
- Circulating MicroRNAs in non-small cell lung cancer: Clinical potential, analytic pitfalls, and barriers to implementationJ Liq Biopsy2026 DecPMID 42840427Review
- Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United StatesJ Med Econ2026 DecPMID 42610318
- Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in SwitzerlandJ Med Econ2026 DecPMID 42565346
- Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501)Int J Cancer2026 Dec 1PMID 42372083
- The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directionsHum Vaccin Immunother2026 DecPMID 42172443Review
- Tailored management of a melanoma patient with bleeding brain metastases and deep vein thrombosis with thrombectomyCNS Oncol2026 DecPMID 42157596
- Decision-making processes among patients with lung cancer considering participation in neoadjuvant immunotherapy clinical trials: A qualitative grounded theory studyAsia Pac J Oncol Nurs2026 DecPMID 42039774
- Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United StatesJ Med Econ2026 DecPMID 41730003
More oncology trends
All specialties →Claudin 18.2
Claudin 18.2 as a target in gastric and oesophageal cancer.
Key point: Zolbetuximab is recommended for patients with gastroesophageal adenocarcinoma, PD-L1 <1, and positive CLDN18.2 expression.
Circulating tumour DNA
Liquid biopsy with ctDNA for detection, monitoring and treatment decisions.
Key point: ctDNA testing may be used when tissue testing is challenging, infeasible, risky, delayed, or required by drug indication; negative/inconclusive results should prompt tissue confirmation.
Antibody-drug conjugates
Antibodies linked to chemotherapy, such as trastuzumab deruxtecan.
Key point: Recent positive phase III trial data have further incorporated ADCs into standard of care in several solid tumours, while predictive biomarker development remains essential.
Bispecific antibodies in solid tumours
Bispecific antibodies such as tarlatamab, amivantamab and ivonescimab.
Personalised cancer vaccines
mRNA and neoantigen vaccines tailored to a patient's tumour.
AI in cancer pathology
Deep learning on digital pathology slides.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(perioperative[tiab] OR neoadjuvant[tiab]) AND (immunotherapy[tiab] OR pembrolizumab[tiab] OR nivolumab[tiab] OR durvalumab[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.